An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD



Status:Completed
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:22 - 68
Updated:1/27/2018
Start Date:September 2014
End Date:June 2017

Use our guide to learn which trials are right for you!

A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects

The purpose of the study is to evaluate the safety and efficacy of the Deep TMS (DTMS)
treatment in subjects with OCD. The device technology is based on the application of deep
brain TMS by means of repetitive pulse trains at a predetermined frequency. The Brainsway
DTMS study is a randomized, 10 week, double blind, multi-center trial comparing active DTMS
treatment to sham treatment.

The OCD study will compare one group of OCD subjects receiving DTMS treatment (HAC-coil) to a
second group of OCD subjects receiving sham treatment (sham coil). The treatment group will
receive 5 weeks of daily DTMS treatments followed by 4 treatments in week 6, for a total of
29 treatment sessions. The control group will receive the same treatments with a sham coil.
Subjects may continue to take SSRI medications (if prescribed) and any other antidepressant
medications will be tapered down prior to the first treatment. SSRI medications approved for
OCD include Fluoxetine (Prozac, Sarafem, Symbyax), Fluvoxamine (Luvox, Luvox CR), Paroxetine
(Paxil, Paxil CR, Pexeva) and Sertraline (Zoloft). Efficacy will be assessed using the
Yale-Brown Obsessive Compulsive Scale score (YBOCS), as well as other efficacy scales. Safety
will be assessed by monitoring of adverse events, vital signs, physical and neurological
examination and using certain safety questionnaires.

Inclusion Criteria:

- • Outpatients

- Men and women 22-68 years of age.

- Subjects diagnosed as suffering from OCD according to the DSM-IV-TR.

- Subjects with at least moderate OCD, rating a YBOCS score of >20.

- Subjects are maintained on SSRI medication at at least a therapeutic dosage for at
least 2 months prior to study entry and for the duration of the trial and/or subjects
are maintained on psychotherapeutic behavioral intervention therapy (subjects
undergoing CBT treatment must be in the maintenance stage (i.e., not during the
assessment or skills acquisition or training stages).

- Subjects with negative responses on the Transcranial Magnetic Stimulation Safety
Screening questionnaire (TASS).

- According to the treating physician the subject is compliant with taking medication,
if applicable.

- Subject is capable and willing to provide informed consent.

- Subject is able to adhere to the treatment schedule.

Exclusion Criteria:

- • Subjects diagnosed according to the SCID I as suffering from any other Axis I diagnosis
as the primary diagnosis.

- Subjects diagnosed according to the SCID II as suffering from severe Personality
Disorder (excluding Obsessive Compulsive Personality Disorder) or hospitalized due to
exacerbation related to borderline personality disorder.

- Present suicidal risk as assessed by the investigator using the Scale for Suicide
Ideation (SSI), brief mental status exam and psychiatric interview or significant
suicide risk based on HDRS-21 item 3 score of 3 or 4 or a history of attempted suicide
in the past year.

- Subject has a history of epilepsy or seizure (EXCEPT those therapeutically induced by
ECT) or history of such in first degree relatives.

- Subject has an increased risk of seizure for any reason, including prior diagnosis of
increased intracranial pressure, or history of significant head trauma with loss of
consciousness for greater than or equal to 5 minutes.

- Subject has a history of head injury necessitating cranial surgery or prolonged coma.

- Subject has a history of any metal in the head including the eyes and ears (outside
the mouth).

- Subject has known history of any metallic particles in the eye, implanted cardiac
pacemaker or any intracardiac lines, implanted neurostimulators, intracranial implant
(e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or
implanted medical pumps.

- Subject has a history of significant hearing loss.

- Subjects with significant neurological disorder or insult including, but not limited
to:

- Any condition likely to be associated with increased intracranial pressure

- Subject has a history of substance abuse including alcoholism within the past 6 months
(except nicotine and caffeine).

- Inadequate communication with the patient.

- Subject is currently participating in another clinical study or enrolled in another
clinical study within 30 days prior to this study.

- Subjects who suffer from an unstable physical, systemic and metabolic disorder such as
unstabilized blood pressure or acute, unstable cardiac disease.

- Subject is currently on any antidepressant medication other than SSRIs.

- Subject is currently on Clomipramine

- Subject has had previous treatment with TMS

- Women who are breast-feeding

- Women who are pregnant or with suspected pregnancy

- Women of childbearing potential and not using a medically accepted form of
contraception when engaging in sexual intercourse.
We found this trial at
11
sites
Royal Palm Beach, Florida 33411
Principal Investigator: Aron Tendler, MD
Phone: 561-267-8876
?
mi
from
Royal Palm Beach, FL
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: John Grant
Phone: 773-834-3778
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
3450 Hull Road
Gainesville, Florida 32610
Principal Investigator: Herb Ward, MD
Phone: 352-281-0032
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Juno Beach, Florida 33408
Principal Investigator: Aron Tendler, MD
Phone: 561-267-8876
?
mi
from
Juno Beach, FL
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Alexander Bystritsky, MD
Phone: 424-256-8246
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Mason, Ohio 45040
Principal Investigator: Leah Cassuto
Phone: 513-536-0721
?
mi
from
Mason, OH
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Wayne Goodman, MD
Phone: 212-659-8803
?
mi
from
New York, NY
Click here to add this to my saved trials
1739 North Ocean Avenue
New York, New York 11777
Principal Investigator: Kyle Lapidus
Phone: 631-509-6111
?
mi
from
New York, NY
Click here to add this to my saved trials
901 5th Avenue
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
San Diego, California 92103
Principal Investigator: David Feifel
Phone: 619-543-5978
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Toronto, Ontario
Principal Investigator: Daniel Blumberger, MD
Phone: 416-5358501
?
mi
from
Toronto,
Click here to add this to my saved trials